Patients with severe COVID-19 who also suffered from a malignant haematological disorder (blood cancer) or had a solid tumour benefited from plasma donations from people who had recovered from the disease or, in particular, from those who had been vaccinated. This was demonstrated by a study presented by co-author Maike Janssen, of Heidelberg University Hospital, Germany, at the European Haematology Congress, which took place in Vienna this year.
It was found that plasma from recovered and vaccinated individuals not only shortened the time taken for these patients’ symptoms to improve. Overall survival was also prolonged. These results also applied to immunosuppressed patients, whose immune systems were likewise unable to respond adequately to infection with SARS-CoV-2.
Previous findings had not demonstrated these positive effects of plasma from people who had recovered from the disease. However, those studies did not differentiate between patients’ baseline conditions.
In this study, 134 patients with COVID-19 and a maximum oxygen saturation of 94 per cent were divided into four groups: cancer patients (Group 1), immunosuppressed patients (Group 2), high-risk patients (Group 3) and patients aged 75 and over (Group 4). Patients on mechanical ventilation were not included. The plasma donations came from donors with a high titre of neutralising antibodies (1:80) following infection with SARS-CoV-2 or at least two doses of an mRNA vaccine. These were administered to half of the patients over two days. The other half (the control group) were treated without receiving plasma.
Although patients in all groups recovered more quickly after receiving plasma, the difference between the plasma group and the control group was not statistically significant. However, when the results from groups 1 and 2 were compared with those of the other groups, a clear difference emerged (13 days versus 31 days). There were also significant differences between these groups in terms of overall survival.
Reference:
European Haematology Congress 2022
Müller-Tidow C. et al., HemaSphere, 2022;6:(S3):371–2
Abstract S282, presented on 10 June 2022